Published in Proc Natl Acad Sci U S A on April 01, 1978
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 5.08
Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A (1995) 4.33
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A (1988) 3.82
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. J Exp Med (1991) 3.30
A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med (1998) 3.03
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics (2004) 2.43
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 2.19
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci (2012) 2.09
Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun (1987) 2.09
Structural basis for complement factor H linked age-related macular degeneration. J Exp Med (2007) 2.02
Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J Exp Med (1980) 1.96
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol (2008) 1.89
Mechanism of action of factor D of the alternative complement pathway. J Exp Med (1978) 1.87
Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med (1999) 1.83
Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. Proc Natl Acad Sci U S A (2003) 1.75
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A (2011) 1.60
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3. J Exp Med (1985) 1.57
Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infect Immun (1992) 1.56
Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A (1981) 1.54
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet (2009) 1.52
Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med (1988) 1.51
Choice of bacteria in animal models of sepsis. Infect Immun (1993) 1.51
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J (1988) 1.41
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood (2017) 1.39
Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Proc Natl Acad Sci U S A (1978) 1.39
Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes. J Exp Med (1982) 1.39
Influence of nutrient limitation and low pH on serogroup B Neisseria meningitidis capsular polysaccharide levels: correlation with virulence for mice. Infect Immun (1985) 1.36
Augmentation of human monocyte opsonin-independent phagocytosis by fragments of human plasma fibronectin. Proc Natl Acad Sci U S A (1981) 1.32
Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1982) 1.32
Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin Microbiol Rev (1989) 1.29
Studies on immune adherence (C3b) receptor activity of human erythrocytes: relationship between receptor activity and presence of immune complexes in serum. Clin Exp Immunol (1982) 1.27
Generation of leukotrienes by human monocytes upon stimulation of their beta-glucan receptor during phagocytosis. Proc Natl Acad Sci U S A (1985) 1.25
The capsular polysaccharide is a major determinant of serum resistance in K-1-positive blood culture isolates of Escherichia coli. Infect Immun (1990) 1.24
Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J (1999) 1.21
Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. J Exp Med (1978) 1.20
Role of fibrinogen in complement inhibition by streptococcal M protein. Infect Immun (1992) 1.17
gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes. J Exp Med (1985) 1.17
Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation. Infect Immun (1992) 1.17
A role for Bacteroides fragilis neuraminidase in bacterial growth in two model systems. Infect Immun (1993) 1.15
Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proc Natl Acad Sci U S A (1986) 1.14
Anaerobic growth and cytidine 5'-monophospho-N-acetylneuraminic acid act synergistically to induce high-level serum resistance in Neisseria gonorrhoeae. Infect Immun (1993) 1.14
Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Proc Natl Acad Sci U S A (1978) 1.13
M protein of the group A Streptococcus binds to the seventh short consensus repeat of human complement factor H. Infect Immun (1998) 1.12
Activation of human monocytes by both human beta 1H and C3b. Immunology (1982) 1.11
Discrimination between host and pathogens by the complement system. Vaccine (2008) 1.11
Lectin receptors as markers for Trypanosoma cruzi. Developmental stages and a study of the interaction of wheat germ agglutinin with sialic acid residues on epimastigote cells. J Exp Med (1980) 1.09
Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1984) 1.07
Novel Aeromonas hydrophila PPD134/91 genes involved in O-antigen and capsule biosynthesis. Infect Immun (2002) 1.06
Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer (2002) 1.05
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol (2012) 1.04
Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun (2007) 1.03
The complotype: dictating risk for inflammation and infection. Trends Immunol (2012) 1.03
Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense. Infect Immun (1986) 1.02
MPGN II--genetically determined by defective complement regulation? Pediatr Nephrol (2006) 1.02
Polyanion-induced self-association of complement factor H. J Immunol (2009) 1.01
gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Immunology (1988) 1.00
Characterization of a novel trans-sialidase of Trypanosoma brucei procyclic trypomastigotes and identification of procyclin as the main sialic acid acceptor. J Exp Med (1993) 0.98
Identification of complement regulatory domains in vaccinia virus complement control protein. J Virol (2005) 0.98
Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. J Virol (2015) 0.97
TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity. Infect Immun (1993) 0.97
Activation of the alternative pathway of human complement by haemoglobin. Clin Exp Immunol (1979) 0.96
Factor H and neisserial pathogenesis. Vaccine (2008) 0.96
Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b. Biochem J (1991) 0.95
Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol (1993) 0.92
Mechanism of induction of complement susceptibility of erythrocytes by spider and bacterial sphingomyelinases. Immunology (2002) 0.92
Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). Infect Immun (1998) 0.92
Activation of the alternative complement pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine. Immunology (1982) 0.91
Activation of the classical and alternative pathways of complement by Treponema pallidum subsp. pallidum and Treponema vincentii. Infect Immun (1987) 0.90
Alternative complement pathway activation increases mortality in a model of burn injury in mice. J Clin Invest (1982) 0.89
Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6-8. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.89
Modulation of complement fixation and the phlogistic capacity of group A, B, and D streptococci by human lysozyme acting on their cell walls. Infect Immun (1986) 0.89
Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro. J Clin Invest (1983) 0.88
The lack of Pneumococcal surface protein C (PspC) increases the susceptibility of Streptococcus pneumoniae to the killing by microglia. Med Microbiol Immunol (2005) 0.88
Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement. J Biol Chem (2011) 0.88
Opsonization of various capsular (K) E. coli by the alternative complement pathway. Immunology (1983) 0.87
The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA. Immunology (1994) 0.86
Natural immunity to Sindbis virus is influenced by host tissue sialic acid content. Proc Natl Acad Sci U S A (1983) 0.85
Resistance of highly pathogenic Naegleria fowleri amoebae to complement-mediated lysis. Infect Immun (1989) 0.85
Antibody enhances killing of Tritrichomonas foetus by the alternative bovine complement pathway. Infect Immun (1990) 0.85
Reduction in alternative complement pathway mediated C3 conversion following burn injury. Ann Surg (1981) 0.85
Regulation of immunoglobulin secretion by factor H of human complement. Immunology (1985) 0.85
Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus. Infect Immun (1983) 0.85
Sendai virus infected cells are readily cytolysed by guinea-pig complement without antibody. Immunology (1981) 0.84
A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus. J Clin Invest (1985) 0.84
Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect Immun (1998) 0.83
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem (1969) 142.11
The thiobarbituric acid assay of sialic acids. J Biol Chem (1959) 43.78
The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science (1954) 21.20
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry (1976) 7.80
Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med (1976) 7.00
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Complement. Annu Rev Biochem (1975) 6.00
Activation of the alternate pathway of human complements by rabbit cells. J Immunol (1974) 5.59
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
Properties of highly purified human properdin. J Immunol (1968) 3.96
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Studies on the chemical and enzymatic modification of glycoproteins. A general method for the tritiation of sialic acid-containing glycoproteins. J Biol Chem (1971) 3.45
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science (1976) 2.70
Lactoperoxidase coupled to polyacrylamide for radio-iodination of proteins to high specific activity. Immunochemistry (1974) 2.25
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
INTERACTION OF AUTOLOGOUS COMPLEMENT WITH RED CELLS IN THE ABSENCE OF ANTIBODY. Proc Soc Exp Biol Med (1964) 1.76
Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. J Exp Med (1976) 1.58
Studies on the sub-unit structure of human properdin. Immunochemistry (1974) 1.57
Calcium requirements for complement dependent hemolytic reactions. J Immunol (1968) 1.47
Modification and introduction of a specific radioactive label into the erythrocyte membrane sialoglycoproteins. Biochem Biophys Res Commun (1972) 1.39
Effect of sialidase on the viability of erythrocytes in circulation. Am J Hematol (1976) 1.29
Modification of sialyl residues of sialoglycoprotein(s) of the human erythrocyte surface. J Biol Chem (1973) 1.28
INTERFERENCE WITH IMMUNE HEMOLYSIS BY GLYCOPROTEIN ANTIGENS. J Exp Med (1964) 1.18
Structure and activation of the early components of complement. Fed Proc (1977) 1.16
Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway. Science (1977) 1.06
Humoral immunostimulation. VII. Sialic acid masks antigenic sites on an antibody-selected bariant cell line. J Immunol (1977) 1.02
Immunological and physiological characteristics of the rapid immune hemolysis of neuraminidase-treated sheep red cells produced by fresh guinea pig serum. J Exp Med (1975) 1.02
Changes in surface carbohydrate of human erythrocytes aged in vivo. Biochem Soc Trans (1975) 1.00
Purification of a human serum protein ("factor E") which enhances cobra venom factor-induced indirect lysis. Identification with the fifth component of complement. Z Immunitatsforsch Exp Klin Immunol (1976) 0.96
pH dependent hemolytic systems. I. Their relationship to paroxysmal nocturnal hemoglobinuria. Blood (1961) 0.92
Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase. J Immunol (1973) 0.91
Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme-pretreated tumor cells. J Immunol (1976) 0.87
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 5.08
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 4.35
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol (1983) 3.79
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med (1982) 3.40
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Action of the C3b-inactivator on the cell-bound C3b. J Immunol (1979) 2.81
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (1992) 2.79
Complement ligand-receptor interactions that mediate biological responses. Annu Rev Immunol (1983) 2.78
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science (1995) 2.68
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63
Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J Exp Med (1981) 2.33
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16
Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol (1989) 2.15
Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest (1983) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol (1987) 1.94
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med (1988) 1.92
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med (1991) 1.88
Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med (2000) 1.87
A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. J Exp Med (1996) 1.86
Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci U S A (1985) 1.81
CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science (1993) 1.80
Lateral distribution and diffusion of the C3b receptor of complement, HLA antigens, and lipid probes in peripheral blood leukocytes. Proc Natl Acad Sci U S A (1980) 1.78
Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes. Proc Natl Acad Sci U S A (1991) 1.78
Opsonin-independent phagocytosis of activators of the alternative complement pathway by human monocytes. J Immunol (1978) 1.71
Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science (1991) 1.63
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol (1988) 1.62
Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med (1986) 1.56
The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol (1983) 1.55
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
PMA induces the ligand-independent internalization of CR1 on human neutrophils. J Immunol (1985) 1.51
C3 requirements for formation of alternative pathway C5 convertase. J Immunol (1976) 1.50
Tissue-specific phosphorylation of complement receptors CR1 and CR2. J Exp Med (1986) 1.48
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med (1988) 1.48
Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med (1998) 1.48
Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med (1993) 1.44
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol (1983) 1.44
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proc Natl Acad Sci U S A (1986) 1.42
Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.41
Lipid monolayer-coated solid surfaces do not perturb the lateral motion and distribution of C3b receptors on neutrophils. J Cell Biol (1982) 1.40
Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Proc Natl Acad Sci U S A (1978) 1.39
Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol (1985) 1.38
Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). J Immunol (1976) 1.38
Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3. J Immunol (1985) 1.37
Seeking wisdom in innate immunity. Nature (1997) 1.37
A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A (1993) 1.36
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med (1989) 1.35
Characterization of human T lymphocytes that express the C3b receptor. J Immunol (1983) 1.35
Self-renewal of B-1 lymphocytes is dependent on CD19. Eur J Immunol (1996) 1.34
p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. J Immunol (1985) 1.32
Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med (1978) 1.32
The identification of N-linked oligosaccharides on the human CR2/Epstein-Barr virus receptor and their function in receptor metabolism, plasma membrane expression, and ligand binding. J Biol Chem (1985) 1.29
CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity (1998) 1.25
Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med (1988) 1.25
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. J Immunol (1978) 1.21
The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. J Immunol (1978) 1.20
Depressed synovial fluid levels of properdin and properdin factor B in patients with rheumatoid arthritis. Arthritis Rheum (1975) 1.18
Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med (1991) 1.18
Selective synthesis of mRNA and proteins by human peripheral blood neutrophils. J Immunol (1988) 1.17
Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med (1991) 1.17
The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol (1991) 1.17
Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med (1989) 1.15
Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J Exp Med (1991) 1.15
Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor. Proc Natl Acad Sci U S A (1988) 1.14
Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Proc Natl Acad Sci U S A (1978) 1.13
Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med (1986) 1.11
IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J Immunol (1981) 1.10
Activation of the alternative complement pathway. CRC Crit Rev Immunol (1979) 1.09
Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. J Immunol (1980) 1.09
Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. J Exp Med (1997) 1.08
The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. J Immunol (1977) 1.08
Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J Immunol (1987) 1.07
Serum proteins involved in decay and regeneration of cobra venom factor-dependent complement activation. J Immunol (1973) 1.06
The signaling activity of murine CD19 is regulated during cell development. J Immunol (1996) 1.06
Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J Immunol (1982) 1.04
Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J Immunol (1991) 1.03
Endocytosis of the C3b receptor of complement within coated pits in human polymorphonuclear leukocytes and monocytes. Lab Invest (1983) 1.03
The human C3b receptor. Springer Semin Immunopathol (1983) 1.02
Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. J Immunol (1989) 1.01
Increased expression of the C3b receptor by neutrophils and complement activation during haemodialysis. Clin Exp Immunol (1984) 1.01
Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity (1997) 1.00